Clinical Trial

The Effects of CGM and Connected Pen in T2DM Treated With Multiple Daily Insulin Injections

Study acronym: Dia2tech
Active, Not Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated November 7, 2024 (before its estimated July 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
The aim of the study is to evaluate the effect of a combination of 12 months treatment with CGM (Freestyle Libre 2) with hypo and hyper alert in combination with a smart pen for bolus insulin (NOVOpen6) on HbA1c and time in range (TIR) in T2DM patients with baseline HbA1c \>53 mmol/mol (7. 0%, eAG 8,6 mmol/l) as compared with standard care.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-03-13.
Status change: Recruiting → Active, Not Recruiting 2024-11-06
Trial Details
NCT Number NCT06311019
Lead Sponsor Klavs Würgler Hansen
Collaborators: Aarhus University Hospital
Conditions Type 2 Diabetes Treated With Insulin
Enrollment 104 participants
Start Date 2024-02-27
Primary Completion 2025-07-01 (estimated)
Study Completion 2025-09-01 (estimated)
Updated on ClinicalTrials.gov 2024-11-07